scholarly journals CHANGES IN THE HAEMOSTASIS SYSTEM UNDER THE INFLUENCE OF TREATMENT OF PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS IN COMBINATION WITH OBESITY USING ADEMETHIONINE, ARGININE GLUTAMATE AND ROSUVASTATIN

2020 ◽  
pp. 42-49
Author(s):  
N. R. Matkovska
Keyword(s):  
Liver Cirrhosis ◽  
Platelet Count ◽  
Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Total Protein ◽  
Alcoholic Liver Cirrhosis ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Pai 1 ◽  
D Dimer

Introduction. The urgency of the problem of liver cirrhosis (LC) is caused by the increase in morbidity, prevalence, life-threatening complications, disability and increasing mortality of able-bodied population. The aim of the study was to examine the effect of complex treatment with ademethionine, arginine glutamate and rosuvastatin on changes in the haemostasis systemin patients with alcoholic liver cirrhosis (ALC) in combination with obesity. Research methods. The study included 105 patients diagnosed with ALC in combination with obesity. The assessment of the effectiveness of a three-month treatment regimen with ademethionine, arginine glutamate and rosuvastatin in obese patients with alcoholic liver cirrhosis (ALC) included indicators of synthetic liver function and hemostasis (total protein, albumin, fibrinogen, platelet count, factor Von Willebrand factor, activated partial thromboplastin time (APTT), thrombin time (TT), international normalized ratio (INR), prothrombin index (PI), D-dimer, tissue plasminogen activator (tPA), 1 plasminogen activator (PAI-1), tPA/PAI-1 index, asymmetric dimethylarginine (ADMA)), as well as liver cirrhosis severity (Child-Pugh score) and 3-month MELD mortality score. Results. Decreased levels of total protein, albumin, fibrinogen, PI, platelet count and increased levels of Von Willebrand factor, prothrombin time (PT), APTT, TT, INR, D-dimer, tPA and PAI-1, ADMA were revealed. Such changes worsened with increasing liver cirrhosis decompensation and were accompanied by an increase in the Child-Pugh and MELD scores (P < 0.05). There was a more pronounced increase in levels of PAI-1 than tPA, that was accompanied by a decrease in tPA/PAI-1 index. A number of researchers indicate that an increase in PAI-1 levels can cause a hypercoagulable state, so its increase with a decrease in tPA/PAI-1 index in patients with ALC in combination with obesity indicates a risk of thrombogenic conditions. This is also evidenced by the increasing number of D-dimers. Therefore, the fibrinolytic/antifibrinolytic factors should be considered in the treatment of such patients to prevent LC complications. Conclusions. The inclusion of ademethionine, arginine glutamate and rosuvastatin in the treatment regimen for 3 months improved the levels of total protein, albumin, fibrinogen, PI, platelet count, Von Willebrand factor, PT, APTT, TT, INR, D-dimer, tPA and PAI-1, ADMA, which was accompanied by a decrease in Child-Pugh severity score and MELD 3-month mortality score.

Associations of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Women's Heart and Health cohort study

2007 ◽  
Vol 14 (5) ◽  
pp. 638-645 ◽  
Author(s):  
Margaret May ◽  
Debbie A. Lawlor ◽  
Rita Patel ◽  
Ann Rumley ◽  
Gordon Lowe ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Incident Coronary Heart Disease ◽  
Tissue Plasminogen ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
D Dimer

Background Associations of three markers of thrombotic tendency, von Willebrand factor, tissue plasminogen activator antigen and fibrin D-dimer, with coronary heart disease have been reported in meta-analyses. It is not known, however, whether findings are generalizable to older women. Design Prospective cohort of 3582 women aged 60-79 years randomly selected from 23 towns without evidence of cardiovascular disease at entry into the British Women's Heart and Health Study. Methods Women were followed for 4.7 years for incident coronary heart disease. Cox proportional hazard models were used to compare the hazard ratio of coronary heart disease per doubling for each thrombotic factor. Results In models adjusting for age and town only there was no association between von Willebrand factor or D-dimer and incidence of coronary heart disease, but there was a positive association of tissue plasminogen activator: coronary heart disease hazard ratio per doubling was 1.37 (95% confidence interval: 1.08-1.75). Adjustment for potential confounders (socio-economic position, smoking, lung function, physical activity, alcohol consumption, body mass index, waist-to-hip ratio) attenuated association to 1.20 (0.92-1.58). Further adjustment for risk factors that may be part of the same pathophysiological process linking tissue plasminogen activator to coronary heart disease (high density lipoprotein cholesterol, triglycerides, blood pressure, fasting glucose, insulin, C-reactive protein, fibrinogen) attenuated the hazard ratio to 1.05 (0.79-1.40). Conclusion In older women, tissue plasminogen activator was associated with incident coronary heart disease, but does not appear to be an independent risk factor for coronary heart disease as the association was attenuated by adjustment for confounding and other metabolic and vascular risk factors. Eur J Cardiovasc Prev Rehabil 14:638-645 © 2007 The European Society of Cardiology

von Willebrand Factor, Soluble P-Selectin, Tissue Plasminogen Activator and Plasminogen Activator Inhibitor in Atherosclerosis

1995 ◽  
Vol 74 (02) ◽  
pp. 626-630 ◽  
Author(s):  
A D Blann ◽  
M Dobrotova ◽  
P Kubisz ◽  
C N McCollum
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Plasminogen Activator Inhibitor ◽  
Tissue Plasminogen ◽  
Soluble P ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Activator Inhibitor ◽  
Pai 1

SummaryTissue plasminogen activator antigen (tPA), plasminogen activator inhibitor antigen (PAI-1), soluble P-selectin and von Willebrand factor antigen (vWf) were measured by ELISA in 41 patients with peripheral vascular disease (PVD), 41 with ischaemic heart disease (IHD) and in 46 age and sex matched asymptomatic controls. Increased vWf was found in patients with IHD (p = 0.0002) and in patients with PVD (p = 0.0011) relative to the controls but levels did not differ between the two patients groups. Raised tPA found in both PVD (p = 0.0006) and IHD (p = 0.0061) compared to the controls also failed to differentiate the two groups of patients. Soluble P-selectin was also raised in both groups (p = 0.003 in IHD and p = 0.0102 in PVD) with no difference between the groups. There were no differences in levels of PAI-1 between the groups. In the subjects taken as a whole, there were significant Spearman’s correlations between tPA and vWf (r = 0.37, p <0.001), tPA and triglycerides (r = 0.38, p <0.001), tPA and P-selectin (r = 0.19, p = 0.032), vWf and age (r = 0.25, p = 0.005) and inversely between vWf and HDL (r = -0.25, p = 0.006). These data support the concept that increased levels of tPA may be important in atherosclerosis, and indicate that soluble P-selectin may be useful in further analysis of the role of platelets and the endothelial cell in this disease.

Severity of venous insufficiency is related to the density of microvascular deposition of PAI-1, uPA and von Willebrand factor

VASA ◽  
2004 ◽  
Vol 33 (1) ◽  
pp. 19-24 ◽  
Author(s):  
Kolbach ◽  
Hamulyák ◽  
Prins ◽  
Neumann ◽  
Cleutjens
Keyword(s):  
Lower Extremity ◽  
Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Venous Insufficiency ◽  
Leg Ulcer ◽  
Significant Difference ◽  
Skin Biopsies ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Pai 1

Background: Impaired microcirculation in chronic venous insufficiency leads to chronic inflammation and dystrophic changes of the skin, and finally to leg ulceration. The purpose of this study was to investigate in more detail coagulation and fibrinolytic protein response of the capillaries in skin biopsies of the lower extremity. Patients and methods: From eighteen ambulant patients with venous leg ulcer(s) (n = 8) and controls (n = 10) with various degrees of venous insufficiency according to the CEAP classification, we obtained 4 mm punch biopsies. Immunohistochemical staining with tissue derived plasminogen activator (tPA), urokinase derived plasminogen activator (uPA), plasminogen activator inhibitor (PAI-1) and von Willebrand Factor (vWF) was performed and analyzed with bright field microscopy. Results: The amount of staining with vWF (p = 0.04) and uPA (p = 0.02) showed statistically significant differences, PAI-1 (p = 0.09) and tPA (p = 0.50) showed no difference between leg ulcer and control groups. A strong proliferation of capillaries with tortuous capillary loops in the papillary dermis was seen, but no statistically significant difference (M-W test, p = 0.10) was found between the groups. Comparison between CEAP classes 0–6 showed a statistically significant increased staining pattern of vWF (p = 0.06), uPA (p = 0.02) and PAI-1 (p = 0.02), but not from tPA (p = 0.30). Conclusions: In skin biopsies of the lower extremity of patients with severe venous insufficiency increased deposition of vWF, PAI-1 and uPA were found in the capillaries. These findings point to a local imbalance in coagulation and fibrinolytic status, which might contribute to impaired microcirculation and finally to the development of venous leg ulceration.

scholarly journals Effects of Losartan on Fibrinolytic Parameters and von Willebrand Factor in Chinese Subjects with Hypertension: A Comparative Study versus Atenolol

2009 ◽  
Vol 37 (3) ◽  
pp. 595-600 ◽  
Author(s):  
J Liu ◽  
N-L Sun ◽  
J Yang ◽  
J-H Huang
Keyword(s):  
Blood Pressure ◽  
Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
Fibrinolytic Parameters ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Chinese Subjects ◽  
Pai 1

To compare the effects of losartan and atenolol on plasma fibrinolytic parameters and von Willebrand factor (vWF), Chinese subjects with mild-to-moderate hypertension were randomized to receive losartan (50 mg/day; n = 30) or atenolol (50 mg/day; n = 30) for 8 weeks. If target blood pressure (< 140/90 mmHg) was not achieved at week 4, hydrochlorothiazide (12.5 mg/day) was also administered. Plasma levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and vWF were determined at baseline and after treatment. Between-group baseline characteristics and blood pressure decrease were comparable. Losartan significantly reduced plasma PAI-1 and vWF and PAI-1/tPA ratio. Atenolol significantly increased plasma tPA, but PAI-1, vWF and PAI-1/tPA ratio were unchanged. In conclusion, losartan, but not atenolol improved the fibrinolytic system and reduced plasma vWF levels in Chinese hypertensives.

scholarly journals Effects of Atenolol or Losartan on Fibrinolysis and von Willebrand Factor in Hypertensive Patients With Left Ventricular Hypertrophy

2009 ◽  
Vol 16 (2) ◽  
pp. 146-152 ◽  
Author(s):  
Kurt Boman ◽  
Jenny Hernestål Boman ◽  
Jonas Andersson ◽  
Mona Olofsson ◽  
Björn Dahlöf
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Tissue Type ◽  
Hypertensive Patients ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Pai 1

Objectives: To compare the effects of the β-blocker atenolol with the angiotensin receptor blocker (ARB) losartan on plasma tissue-type plasminogen activator (tPA) activity and mass concentration, plasminogen activator inhibitor-1 (PAI-1) activity, tPA/PAI-1 complex, and von Willebrand factor (VWF). Design: A prespecified, explorative substudy in 22 patients with hypertension and left ventricular hypertrophy (LVH) performed within randomized multicenter, double-blind prospective study. Results: After a median of 36 weeks of treatment, there were significant differences between the treatment groups, atenolol versus losartan, in plasma median levels of tPA mass (11.9 vs 7.3 ng/mL, P = .019), PAI-1 activity (20.7 vs 4.8 IU/mL, P = .030), and tPA/PAI-1 complex (7.1 vs 2.5 ng/mL, P = .015). In patients treated with atenolol, median levels of tPA mass (8.9-11.9 ng/mL, P = .021) and VWF (113.5%-134.3%, P = .021) increased significantly, indicating a change toward a more prothrombotic state. No significant changes occurred in the losartan group. Conclusion: Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group. These findings suggest different fibrinolytic and hemostatic responses to treatment in hypertensive patients with LVH.

scholarly journals Fibrin D-Dimer, Tissue-Type Plasminogen Activator, von Willebrand Factor, and Risk of Incident Stroke in Older Men

Stroke ◽  
2012 ◽  
Vol 43 (5) ◽  
pp. 1206-1211 ◽  
Author(s):  
S. Goya Wannamethee ◽  
Peter H. Whincup ◽  
Lucy Lennon ◽  
Ann Rumley ◽  
Gordon D. Lowe
Keyword(s):  
Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Older Men ◽  
Tissue Type ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
D Dimer
Sign in / Sign up

Export Citation Format

Share Document